NZ514350A - Compositions and methods for effecting the levels of cholesterol - Google Patents

Compositions and methods for effecting the levels of cholesterol

Info

Publication number
NZ514350A
NZ514350A NZ51435000A NZ51435000A NZ514350A NZ 514350 A NZ514350 A NZ 514350A NZ 51435000 A NZ51435000 A NZ 51435000A NZ 51435000 A NZ51435000 A NZ 51435000A NZ 514350 A NZ514350 A NZ 514350A
Authority
NZ
New Zealand
Prior art keywords
cholesterol
effecting
compositions
levels
methods
Prior art date
Application number
NZ51435000A
Inventor
Michael Jaye
Kevin J Lynch
Dilip V Amin
Kim-Anh Thi Doan
Dawn Marchadier
Cyrille Maugeais
Daniel J Rader
John A Krawiec
Victoria J South
Original Assignee
Aventis Pharma Inc
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Application filed by Aventis Pharma Inc, Univ Pennsylvania filed Critical Aventis Pharma Inc
Publication of NZ514350A publication Critical patent/NZ514350A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ51435000A 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol NZ514350A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
PCT/US2000/007870 WO2000057837A2 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol

Publications (1)

Publication Number Publication Date
NZ514350A true NZ514350A (en) 2004-12-24

Family

ID=23060703

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ51435000A NZ514350A (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol
NZ531180A NZ531180A (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ531180A NZ531180A (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide

Country Status (13)

Country Link
EP (1) EP1171078A4 (en)
JP (1) JP2002540127A (en)
KR (2) KR100887164B1 (en)
AU (1) AU776684B2 (en)
BR (1) BR0009333A (en)
CA (1) CA2363486C (en)
HK (1) HK1043309A1 (en)
IL (2) IL145526A0 (en)
MX (1) MXPA01009727A (en)
NO (2) NO331779B1 (en)
NZ (2) NZ514350A (en)
WO (1) WO2000057837A2 (en)
ZA (1) ZA200107598B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
CN101437933B (en) 2005-12-28 2013-11-06 斯克里普斯研究所 Natural antisense and non-coding RNA transcripts as drug targets
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
JP6091752B2 (en) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Treatment of erythropoietin (EPO) -related diseases by suppression of natural antisense transcripts against EPO
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
DK2396038T3 (en) 2009-02-12 2016-02-01 Curna Inc TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
CA2755404C (en) 2009-03-17 2020-03-24 Joseph Collard Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
CN102803492B (en) 2009-05-06 2016-06-29 库尔纳公司 TTP relevant disease is treated for the natural antisense transcript of triple four proline (TTP) by suppression
EP2427553A4 (en) 2009-05-06 2012-11-07 Opko Curna Llc Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
EP2427554B1 (en) 2009-05-08 2016-11-16 CuRNA, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR101704988B1 (en) 2009-05-28 2017-02-08 큐알엔에이, 인크. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
ES2629339T3 (en) 2009-06-16 2017-08-08 Curna, Inc. Treatment of diseases related to paraoxonase 1 (pon1) by inhibition of natural antisense transcript to pon1
KR101801404B1 (en) 2009-06-16 2017-12-20 큐알엔에이, 인크. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2618894T3 (en) 2009-06-24 2017-06-22 Curna, Inc. TREATMENT OF DISEASES RELATED TO THE RECEIVER OF THE TUMOR NECROSIS FACTOR 2 (TNFR2) BY INHIBITION OF THE ANTISENTED NATURAL TRANSCRIPT FOR TNFR2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
KR101802536B1 (en) 2009-08-05 2017-11-28 큐알엔에이, 인크. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
US9044493B2 (en) 2009-08-11 2015-06-02 Curna, Inc. Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
CA2771228C (en) 2009-08-21 2020-12-29 Opko Curna, Llc Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
CA2771172C (en) 2009-08-25 2021-11-30 Opko Curna, Llc Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
DK2480669T3 (en) 2009-09-25 2018-02-12 Curna Inc TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY
RU2639550C2 (en) 2009-12-16 2017-12-21 Курна, Инк. Treatment of diseases connected with site-1 membrane-impacted peptidase of transcription factors (mbtps1), by inhibiting natural antisense transcript to mbtps1
JP6031356B2 (en) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2.
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
KR101853508B1 (en) 2009-12-29 2018-06-20 큐알엔에이, 인크. TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
RU2016115782A (en) 2009-12-31 2018-11-28 Курна, Инк. TREATMENT OF DISEASES ASSOCIATED WITH THE SUBSTRATE OF THE INSULIN 2 RECEPTOR (IRS2) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND THE TRANSCRIPTION FACTOR E3 (TFE3)
KR101878501B1 (en) 2010-01-04 2018-08-07 큐알엔에이, 인크. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
ES2671877T3 (en) 2010-01-25 2018-06-11 Curna, Inc. Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1
KR101838308B1 (en) 2010-02-22 2018-03-13 큐알엔에이, 인크. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
RU2612884C2 (en) 2010-04-02 2017-03-13 Курна, Инк. Treatment of diseases associated with colonystimulating factor 3 (csf3) by inhibition of natural antisense transcript to csf3
JP5978203B2 (en) 2010-04-09 2016-08-24 カッパーアールエヌエー，インコーポレイテッド Treatment of fibroblast growth factor (FGF21) fibroblast growth factor FGF21) related diseases by inhibition of natural antisense transcripts against FGF21
KR101915115B1 (en) 2010-05-03 2018-11-05 큐알엔에이, 인크. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI586356B (en) 2010-05-14 2017-06-11 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
NO2576784T3 (en) 2010-05-26 2018-04-14
RU2585229C2 (en) 2010-05-26 2016-05-27 Курна, Инк. Treatment of diseases associated with atonal homolog 1 (aton1) by inhibiting natural antisense transcript of gene aton1
PT2585596T (en) 2010-06-23 2021-03-23 Curna Inc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2012009402A2 (en) 2010-07-14 2012-01-19 Opko Curna Llc Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
CN103459599B (en) 2010-11-23 2017-06-16 库尔纳公司 NANOG relevant diseases are treated by suppressing the natural antisense transcript of NANOG
CA2838588C (en) 2011-06-09 2021-09-14 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
WO2013036403A1 (en) 2011-09-06 2013-03-14 Curna, Inc. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
KR20140136488A (en) 2012-03-15 2014-11-28 큐알엔에이, 인크. Treatment of brain derived neurotrophic factor(bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN102628060A (en) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 Production method of low-fat milk
WO2014069651A1 (en) * 2012-11-05 2014-05-08 塩野義製薬株式会社 Method for evaluating drug activity of medicine having therapeutic or preventive effect on disease to which el activity relates, and method for screening for el activity inhibitory substance
JP6304775B2 (en) 2013-03-14 2018-04-04 塩野義製薬株式会社 Monoclonal antibodies that inhibit the enzymatic activity of vascular endothelial lipase
TWI734410B (en) 2014-09-11 2021-07-21 日商塩野義製藥股份有限公司 Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US20240277861A1 (en) * 2021-07-26 2024-08-22 Purotech Bio, Inc. Anti-hepatitis b virus agent targeting host factor lipg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013791A1 (en) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
EP0948609B1 (en) * 1996-12-06 2005-03-16 Aventis Pharmaceuticals Inc. Llg polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
AU1941899A (en) * 1997-12-19 1999-07-12 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Also Published As

Publication number Publication date
NZ531180A (en) 2005-06-24
EP1171078A2 (en) 2002-01-16
WO2000057837A8 (en) 2001-09-27
CA2363486C (en) 2012-12-18
IL145526A0 (en) 2002-06-30
CA2363486A1 (en) 2000-10-05
EP1171078A4 (en) 2002-11-06
WO2000057837A2 (en) 2000-10-05
NO20100214L (en) 2001-11-21
WO2000057837A3 (en) 2001-01-25
JP2002540127A (en) 2002-11-26
NO20014657D0 (en) 2001-09-25
KR100887164B1 (en) 2009-03-10
NO20014657L (en) 2001-11-21
NO331784B1 (en) 2012-03-26
WO2000057837A9 (en) 2001-10-18
ZA200107598B (en) 2003-05-28
NO331779B1 (en) 2012-03-26
BR0009333A (en) 2002-01-08
KR20020029651A (en) 2002-04-19
HK1043309A1 (en) 2002-09-13
MXPA01009727A (en) 2002-07-22
AU3918700A (en) 2000-10-16
IL145526A (en) 2010-11-30
AU776684B2 (en) 2004-09-16
KR20050044812A (en) 2005-05-12

Similar Documents

Publication Publication Date Title
NZ514350A (en) Compositions and methods for effecting the levels of cholesterol
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
EP1212065A4 (en) Compositions and methods for raising hdl cholesterol levels
GB2364059B (en) Beta-Secretase enzyme compositions and methods
EP1177277A4 (en) Compositions and methods for the modification of gene transcription
AUPQ419099A0 (en) Novel compositions and methods
GB2348808B (en) Methods and compositions for desensitisation
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
AU2212299A (en) Compositions and methods for the treatment of tumor
IL148803A0 (en) Novel composition and method for stabilizing the same
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
EP1139981A4 (en) Compositions and methods of using the same
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
EP1163340A4 (en) Compositions and methods for the modification of gene expression
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
EP1207896A4 (en) Methods and compositions for reducing serum phosphate levels
GB0318112D0 (en) ›-Secretase enzyme compositions and methods
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU4388899A (en) Novel compositions for the treatment of atherosclerosis and related conditions
AU5931300A (en) Ringene compositions and methods for use thereof
AU7606700A (en) Polyester-wax compositions and methods of making the same
HUP0100613A3 (en) Methods and compositions for stabilizing acetylcholine compositions

Legal Events

Date Code Title Description
PSEA Patent sealed
S35A Application for proceedings under section 35 (restoration of lapsed patents)
RENW Renewal (renewal fees accepted)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 24 MAR 2020 BY CPA GLOBAL

Effective date: 20130211

EXPY Patent expired